Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that the United States Patent and Trademark Office (USPTO) recently issued two new patents related to the company’s novel self-amplifying mRNA (samRNA) vaccine platform technology.